GlassScriptPhysician profile
William T Johanson
NPI 1316987043
$9,648.43
in general payments reported to CMS, 2019-2025
48 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2020: $1,033 · 2021: $2,104 · 2022: $1,768 · 2023: $1,826 · 2024: $1,276 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,205.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,460.67 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Abbvie INC. | $1,269.25 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $642.80 | 2019-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $554.47 | 2019-2025 | Ingrezza |
| Bayer Healthcare Pharmaceuticals INC. | $533.38 | 2021-2025 | |
| Novo Nordisk INC | $509.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $425.29 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Sunovion Pharmaceuticals INC. | $397.53 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $385.03 | 2019-2025 | Invega Sustenna |
| Astrazeneca Pharmaceuticals LP | $291.85 | 2020-2025 | Airsupra, Farxiga |
| Aimmune Therapeutics, INC. | $247.79 | 2024-2025 | Zenpep |
| Alkermes, INC. | $237.85 | 2019-2025 | Lybalvi, Aristada, Vivitrol |
| Gilead Sciences, INC. | $221.66 | 2023-2025 | |
| Pfizer INC. | $214.48 | 2019-2025 | |
| Indivior INC. | $182.13 | 2019-2025 | Sublocade |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $169.89 | 2019-2023 | Veozah |
| Phathom Pharmaceuticals, INC. | $167.00 | 2024-2025 | Voquezna |
| Abbott Laboratories | $166.88 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Exact Sciences Corporation | $163.66 | 2025 | The Cologuard Plus Collection Kit |
| Vanda Pharmaceuticals INC. | $143.08 | 2019-2023 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $121.94 | 2022-2025 | Caplyta |
| Paratek Pharmaceuticals, INC. | $119.69 | 2022-2023 | Nuzyra |
| Nestle Healthcare Nutrition INC. | $118.02 | 2021 | |
| Lundbeck LLC | $105.61 | 2020-2023 | Rexulti |
| Allergan, INC. | $87.47 | 2020 | |
| Eisai INC. | $62.05 | 2020-2024 | |
| Almatica Pharma LLC | $58.74 | 2022 | |
| Scilex Pharmaceuticals INC. | $52.67 | 2019 | |
| Forte Bio-Pharma LLC | $50.46 | 2022 | |
| Mylan Specialty L.P. | $48.64 | 2022-2023 | Yupelri |
| Ascensia Diabetes Care US INC. | $41.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $41.26 | 2019-2020 | |
| Shield Therapeutics INC | $41.14 | 2023 | Accrufer |
| Dexcom, INC. | $39.91 | 2023-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company LTD. | $35.82 | 2022 | |
| Uswm, LLC | $26.75 | 2021 | |
| Amgen INC. | $25.35 | 2023 | Tezspire |
| Sanofi-Aventis U.S. LLC | $23.14 | 2023 | |
| Medtronic, INC. | $21.80 | 2022 | |
| Edwards Lifesciences Corporation | $20.16 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Xeris Pharmaceuticals, INC. | $18.42 | 2023 | Gvoke Hypopen |
| Viatris Specialty LLC | $18.18 | 2025 | Yupelri |
| Glaxosmithkline, LLC. | $16.85 | 2020 | |
| Biogen, INC. | $16.53 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.52 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.36 | 2022 | |
| Mdd US Operations, LLC | $13.11 | 2020 | |
| Kaleo, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Johanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.